Avenue Therapeutics, Inc. financial data

Symbol
ATXI on Nasdaq
Location
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 159 %
Return On Equity -285 %
Return On Assets -137 % +28.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.43M shares -82.5%
Common Stock, Shares, Outstanding 1.19M shares -85%
Entity Public Float 8.52M USD +189%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 1.12M shares +981%
Weighted Average Number of Shares Outstanding, Diluted 8.2M shares +459%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.64M USD +13.3%
General and Administrative Expense 5.08M USD -11.2%
Operating Income (Loss) -10.7M USD +28.2%
Nonoperating Income (Expense) 122K USD
Net Income (Loss) Attributable to Parent -2.69M USD +32.8%
Earnings Per Share, Basic 118 USD/shares +83.4%
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.92M USD +213%
Assets 4.99M USD +199%
Accounts Payable, Current 78K USD -39.5%
Liabilities, Current 1.16M USD -85.1%
Liabilities 1.16M USD -85.1%
Retained Earnings (Accumulated Deficit) -98M USD -6.37%
Stockholders' Equity Attributable to Parent 4.76M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.83M USD
Liabilities and Equity 4.99M USD +199%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.12M USD -98.3%
Net Cash Provided by (Used in) Financing Activities 4.53M USD +46.1%
Common Stock, Shares Authorized 200M shares +167%
Common Stock, Shares, Issued 1.19M shares -85%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.71M USD +78.3%
Deferred Tax Assets, Valuation Allowance 35.7M USD +15.2%
Deferred Tax Assets, Gross 35.7M USD +15.2%
Deferred Tax Assets, Operating Loss Carryforwards 27.3M USD +6.46%
Preferred Stock, Shares Issued 250K shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 103M USD +18.4%
Preferred Stock, Shares Outstanding 250K shares
Share-based Payment Arrangement, Expense 1.25M USD +611%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%